Drug Screening Using IMD in Bladder Cancer

The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.

Methotrexate will be placed in reservoir 1 of the implantable microdevice.

Carboplatin will be placed in reservoir 2 of the implantable microdevice.

Avelumab will be placed in reservoir 3 of the implantable microdevice.

Paclitaxel will be placed in reservoir 4 of the implantable microdevice.

Vinblastine will be placed in reservoir 5 of the implantable microdevice.

Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.

(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.

Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.

Cisplatin will be placed in reservoir 9 of the implantable microdevice.

Nivolumab will be placed in reservoir 10 of the implantable microdevice.

Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.

Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.

(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.

(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.

Erdafitinib will be placed in reservoir 15 of the implantable microdevice.

(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.

Gemcitabine will be placed in reservoir 17 of the implantable microdevice.

(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.

Enfortumab will be placed in reservoir 19 of the implantable microdevice.

Sacitzumab will be placed in reservoir 20 of the implantable microdevice.